Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. METHODS: We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. RESULTS: Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. CONCLUSIONS: In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The KRd regimen has been shown to be effective in a randomized trial, and is a major option for the treatment of relapsed disease (Table 8).67”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [67]
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [27]
In the citing paper
“Pomalidomide is most often used in combination with dexamethasone, either alone or as part of triplet regimens with a variety of other anti-myeloma agents, including bortezomib45, daratumumab46 or elotuzumab47.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [46]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 2×
“The standard-risk group consisted of patients without t(4;14) or t(14;16) and with deletion 17p in less than 60% of plasma cells.”
BackgroundDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Cited by
Items 201–300 of 1,000
Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
Zhang, K. W., Stockerl-Goldstein, K. E., & Lenihan, D. J. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.002 · Cited by 64
“As compared with lenalidomide and dexamethasone alone, the addition of carfilzomib in relapsed MM improved 24-month survival by 21% and also led to significant improvement in hematologic response rate (27).”
ResultKumar, S., Baizer, L., Callander, N. S., Giralt, S. A., Hillengass, J., Freidlin, B., Hoering, A., Richardson, P. G., Schwartz, E. I., Reiman, A., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00695-5 · Cited by 62
“Previously mentioned regimens such a EloPd, DPd, Isa-Pd, KCd, or KRd would be reasonable choices in bortezomib refractory patients relapsing in the first line, although some are not yet FDA-approved for second line treatment.”
BackgroundInfluentialMultiple myeloma cancer stem cells
Gao, M., Kong, Y., Yang, G., Gao, L., & Shi, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8154 · Cited by 59
Kistler, K. D., Kalman, J., Sahni, G., Murphy, B., Werther, W., Rajangam, K. L., & Chari, A. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.11.009 · Cited by 66
“8%, respectively.(55) A recently published study of 32 intensively treated and multiply relapsed MM survivors found that most patients had established cardiovascular and/ or respiratory dysfunction, greater than the levels expected in the general population of a similar age.”
BackgroundUterine fibroid therapy using interventional radiology mini-invasive treatments: current perspective
Masciocchi, C., Arrigoni, F., Ferrari, F., Giordano, A. V., Iafrate, S., Capretti, I., Cannizzaro, E., Reginelli, A., Ierardi, A. M., Floridi, C., et al. (2017) · Medical Oncology · doi:10.1007/s12032-017-0906-5 · Cited by 62
Dent, S. F., Kikuchi, R., Kondapalli, L., Ismail-Khan, R. R., Brezden‐Masley, C., Barac, A., & Fradley, M. G. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_286019 · Cited by 66
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
Thakurta, A., Pierceall, W. E., Amatangelo, M. D., Flynt, E., & Agarwal, A. (2021) · Oncotarget · doi:10.18632/oncotarget.27973 · Cited by 66
Solimando, A. G., Vià, M. D., Cicco, S., Leone, P., Lernia, G. D., Giannico, D., Desantis, V., Frassanito, M. A., Morizio, A., Tascon, J. D., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070997 · Cited by 62
“The authors reported that in the KRD cohort, there was a significant increase in responses (87% vs. 67%, p < 0.001) and in survival rates at two years (median PFS 26.3 months vs. 17.6 months, 95% CI: 0.57–0.83, p = 0.0001; OS 73% vs. 65%, 95% CI: 0.63–0.99, p = 0.04).”
BackgroundInfluentialCarfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
Landgren, O., Sonneveld, P., Jakubowiak, A. J., Mohty, M., Iskander, K. S., Mezzi, K., & Siegel, D. S. D. (2019) · Leukemia · doi:10.1038/s41375-019-0517-6 · Cited by 64
Self-citationRoy, A. N., Kish, J. K., Bloudek, L. M., Siegel, D. S. D., Jagannath, S., Globe, D., Kuriakose, E. T., & Migliaccio–Walle, K. (2015) · PubMed Central · Cited by 67
Self-citationPanobinostat for the Management of Multiple Myeloma
Sivaraj, D., Green, M. M., & Gasparetto, C. (2016) · Future Oncology · doi:10.2217/fon-2016-0329 · Cited by 65
Panobinostat and Multiple Myeloma in 2018
Yee, A. J., & Raje, N. S. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0644 · Cited by 61
Botta, C., Ciliberto, D., Rossi, M., Staropoli, N., Cucè, M., Galeano, T., Tagliaferri, P., & Tassone, P. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003905 · Cited by 67
Heider, M., Eichner, R., Stroh, J., Morath, V., Kuisl, A., Zecha, J., Lawatscheck, J., Baek, K., Garz, A.-K., Rudelius, M., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.046 · Cited by 62
Fhu, C. W., & Ali, A. (2021) · Cancers · doi:10.3390/cancers13071513 · Cited by 65
“It possesses a more selective mechanism of action and exhibits high chemical stability, which is shown by fewer side effects when compared to bortezomib [176,177].”
BackgroundAdditivity predicts the efficacy of most approved combination therapies for advanced cancer
Hwangbo, H., Patterson, S. C., Dai, A., Plana, D., & Palmer, A. C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00667-z · Cited by 71
Chng, W.-J., Goldschmidt, H., Dimopoulos, M. A., Moreau, P., Joshua, D. E., Palumbo, A. P., Facon, T. T. F., Ludwig, H., Pour, L., Niesvizky, R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.390 · Cited by 60
Self-citationUpdate on the optimal use of bortezomib in the treatment of multiple myeloma
Mohan, M., Matin, A., & Davies, F. E. (2017) · Cancer Management and Research · doi:10.2147/cmar.s105163 · Cited by 61
Arterial thrombosis and cancer
Aronson, D., & Brenner, B. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.01.003 · Cited by 60
Kumar, S. K., Moreau, P., Hari, P., Mateos, M., Ludwig, H., Shustik, C., Masszi, T., Spencer, A. G., Hájek, R., Romeril, K. R., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14733 · Cited by 59
Self-citationUpdate on the role of lenalidomide in patients with multiple myeloma
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718775629 · Cited by 61
How to Treat High-Risk Myeloma at Diagnosis and Relapse
Caro, J., Hadidi, S. A., Usmani, S. Z., Yee, A. J., Raje, N. S., & Davies, F. E. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320105 · Cited by 59
Hideshima, T., Cottini, F., Nozawa, Y., Seo, H., Ohguchi, H., Samur, M., Cirstea, D. D., Mimura, N., Iwasawa, Y., Richardson, P. G. G., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738500 · Cited by 60
Orgueira, A. M., González, M. S., Arias, J. Á. D., Rodríguez, B. A., Vence, N. A., López, Á. B., Blanco, A. A., Pérez, L. B., Raíndo, A. P., López, M. C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01286-2 · Cited by 66
Self-citationHow I manage the toxicities of myeloma drugs
Delforge, M., & Ludwig, H. (2017) · Blood · doi:10.1182/blood-2017-01-725705 · Cited by 58
“Additionally, carfilzomib may cause cardiovascular toxicity such as hypertension (in around 15%) and - rarely but more importantly- cardiac failure (see table 1).(6,7) According to phase II(40) and III(6,7) For personal use only.”
BackgroundSelf-citationEvaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
Dima, D., Dower, J., Comenzo, R. L., & Varga, C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s212526 · Cited by 59
Ramasamy, K., Gay, F., Weisel, K. C., Zweegman, S., Mateos, M., & Richardson, P. G. G. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100808 · Cited by 59
Self-citationTreatment of relapsed multiple myeloma: Evidence-based recommendations
Durer, C., Durer, S., Lee, S., Chakraborty, R., Malik, M. N., Rafae, A., Zar, M. A., Kamal, A., Rosko, N., Samaras, C. J., et al. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100616 · Cited by 59
Stefano, V. D., Larocca, A., Carpenedo, M., Cavo, M., Raimondo, F. D., Falanga, A., Offidani, M., Petrucci, M. T., Ruggeri, M., Santi, R. M., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280893 · Cited by 61
“In the ASPIRE trial, carfilzomib/lenalidomide/dexamethasone (KRD) had a VTE incidence of 13% while lenalidomide/dexamethasone (DR) had 6%.(38) In a retrospective study of 305 newly diagnosed MM patients, VTE rates in those treated with KRD or bortezomib, lenalidomide, and dexamethasone (RVD) were significantly differe…”
BackgroundCheikh, J. E., Moukalled, N. M., Malard, F., Bazarbachi, A. A., & Mohty, M. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00849-z · Cited by 57
Current treatments for renal failure due to multiple myeloma
Gavriatopoulou, M., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1236915 · Cited by 59
“In the phase III ASPIRE study (lenalidomide–dexamethasone ± carfilzomib), the eligible patients had to have a CrCl ≥ 50 ml/min [70].”
BackgroundSelf-citationCereblon binding molecules in multiple myeloma
Kortüm, K. M., Zhu, Y. X., Shi, C., Jedlowski, P. M., & Stewart, A. K. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.03.003 · Cited by 61
Self-citationMultiple myeloma in the very elderly patient: challenges and solutions
King, A. J., Eyre, T. A., Sharpley, F. A., Watson, C. S., Ramasamy, K., & Willan, J. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s89465 · Cited by 58
Novel targets in the treatment of chronic graft-versus-host disease
Im, A., Hakim, F. T., & Pavletic, S. Z. (2016) · Leukemia · doi:10.1038/leu.2016.367 · Cited by 54
Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation
Çetin, A. E., Stevens, M. M., Calistri, N. L., Fulciniti, M., Olçum, S., Kimmerling, R. J., Munshi, N. C., & Manalis, S. R. (2017) · Nature Communications · doi:10.1038/s41467-017-01593-2 · Cited by 58
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 56
Proteasome inhibitors for multiple myeloma
Okazuka, K., & Ishida, T. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy108 · Cited by 60
Kaufman, J. L., Mina, R., Jakubowiak, A. J., Zimmerman, T. L., Wolf, J. J., Lewis, C. M., Gleason, C. L., Sharp, C., Martin, T. G., Heffner, L. T., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-018-0154-8 · Cited by 54
Self-citationGupta, N., Hanley, M. J., Harvey, R. D., Badros, A. Z., Lipe, B. C., Kukreti, V., Berdeja, J. G., Yang, H., Hui, A., Qian, M. G., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14125 · Cited by 53
“However, patients with CrCl 50 ml/min were not included in the subsequent phase 3 trial evaluating carfilzomib, lenalidomide and dexamethasone (Stewart et al, 2015).”
BackgroundSelf-citationIxazomib for the treatment of multiple myeloma
Gentile, M., Offidani, M., Vigna, E., Corvatta, L., Recchia, A. G., Morabito, L., Morabito, F., & Gentili, S. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1065250 · Cited by 54
“Ixazomib ± Dex [41] CarDex (CHAMPION-1) [42] CarDex (ENDEAVOR) [37] CRD (ASPIRE) [36]”
BackgroundResultUpdate of thrombosis in multiple myeloma
Leebeek, F. W. G. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30103-7 · Cited by 53
Chen-Scarabelli, C. A., Corsetti, G., Pasini, E., Dioguardi, F. S., Sahni, G., Narula, J., Gavazzoni, M., Patel, H., Saravolatz, L. I. I., Knight, R. A., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.024 · Cited by 57
Jakubowiak, A. J., Campioni, M., Benedict, Á., Houisse, I., Tichy, E., Giannopoulou, A., Aggarwal, S. K., Barber, B., & Panjabi, S. S. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1194278 · Cited by 52
Self-citationNovel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Chhabra, S. (2017) · Pharmaceuticals · doi:10.3390/ph10020040 · Cited by 55
“Stewart AK [38] ASPIRE III RRMM 1–3 KRd vs.”
BackgroundDíaz, T., Rodríguez, V., Lozano, E., Mena, M.-P., Calderón, M., Rosiñol, L., Martínez, A., Tovar, N., Pérez‐Galán, P., Bladé, J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.164632 · Cited by 55
Self-citationTreatment of relapsed and refractory multiple myeloma
Lee, J. H., & Kim, S. (2020) · Blood Research · doi:10.5045/br.2020.s008 · Cited by 55
“Further, studies on Rd with or without carfilzomib (ASPIRE) [21], elotuzumab (ELOQUENT-2) [22], and daratumumab (POLLUX) [23] have reported that these drugs improve pro- gression-free survival (PFS) but not significantly.”
BackgroundInsights on Multiple Myeloma Treatment Strategies
Mateos, M., Ludwig, H., Bazarbachi, A. A., Beksaç, M., Bladé, J., Boccadoro, M., Cavo, M., Delforge, M., Dimopoulos, M. A., Facon, T. T. F., et al. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000163 · Cited by 55
“0001).(65) An OS benefit for KRd over Rd was recently”
BackgroundSelf-citationMoreau, P., Kolb, B., Attal, M., Caillot, D., Benboubker, L., Tiab, M., Touzeau, C., Leleu, X., Roussel, M., Chaleteix, C., et al. (2015) · Blood · doi:10.1182/blood-2015-02-626168 · Cited by 51
Self-citationon behalf of the GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group, Arana, P., Paiva, B., Cedena, M. ‐., Puig, N., Cordón, L., Vídriales, M., Gutierrez, N. C., Chiodi, F., Burgos, L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.320 · Cited by 52
Self-citationCost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States
Carlson, J. J., Guzauskas, G. F., Chapman, R. H., Synnott, P. G., Liu, S., Russo, E. T., Pearson, S. D., Brouwer, E., & Ollendorf, D. A. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.1.29 · Cited by 52
“, 2013(24)), drug costs, dosage intensity, and health state utilities.(6) Probabilistic sensitivity analysis showed variability in model outcomes (Figure 1).”
BackgroundMethodResultGhobrial, I. M., Vij, R., Siegel, D. S. D., Badros, A. Z., Kaufman, J. L., Raje, N. S., Jakubowiak, A. J., Savona, M. R., Obreja, M., & Berdeja, J. G. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3728 · Cited by 52
“Carfilzomib has been associatedwith cardiac and renal events in phase II and III studies (8, 9, 21).”
BackgroundSelf-citationHow I treat relapsed multiple myeloma
Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2022) · Blood · doi:10.1182/blood.2020008734 · Cited by 55
Self-citationKazandjian, D., Hill, E., Dew, A., Morrison, C., Roswarski, J., Korde, N., Emanuel, M., Petrosyan, A., Bhutani, M., Calvo, K. R., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3971 · Cited by 49
Schmitz, S., Maguire, Á., Morris, J., Ruggeri, K., Haller, E., Kuhn, I., Leahy, J., Homer, N., Khan, A., Bowden, J., et al. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0509-7 · Cited by 48
Ao, L., Reichel, D., Hu, D., Jeong, H., Kim, K. B., Bae, Y., & Lee, W. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.226993 · Cited by 49
“In this regard, previous studies have demonstrated that PEG-PCL–based polymer micelle particles carrying the anticancer agent paclitaxel exerted more potent anticancer activity in a mouse xenograft model than taxol alone (Tan et al., 2013).”
BackgroundResultInfluentialLaubach, J. P., Moslehi, J. J., Francis, S. A., San Miguel, J. F., Sonneveld, P., Orlowski, R. Z., Moreau, P., Rosiñol, L., Faber, E. A., Voorhees, P., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14708 · Cited by 49
Self-citationNew Agents in Multiple Myeloma: An Examination of Safety Profiles
Bringhen, S., de Wit, E., & Dimopoulos, M. A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.05.003 · Cited by 55
“…PX-171-004,37 PX-171-00538 CAR alone 24 3 5 4 4 1 FOCUS: Hajek et al (2017)40 CAR alone 8 2 10 8 6 5 Low-dose DEX (or equivalent) 7 1 4 3 2 1 ASPIRE: Stewart et al (2015)41 CAR þ LEN þ DEX 7 1 8 3 e e LEN þ DEX 5 1 7 3 e e ENDEAVOR: Dimopoulos et al (2016)42 CAR þ DEX e e 8 4 e e BOR þ DEX…”
BackgroundInfluentialSelf-citationBringhen, S., Mina, R., Cafro, A. M., Liberati, A. M., Spada, S., Belotti, A., Gaïdano, G., Patriarca, F. F., Troia, R., Fanin, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0024-1 · Cited by 49
Self-citationChemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
Moon, S., & Lee, B. (2018) · PubMed Central · doi:10.14348/molcells.2018.0372 · Cited by 57
“For example, following a path similar to that for kinase inhibitors, bortezomib and its progeny have been successfully developed as FDA-approved anticancer drugs for the treatment of multiple myeloma (MM) and other blood cancers, and in fact, these agents are proteasome inhibitors that block the proteolytic reaction (…”
BackgroundInfluentialHarrison, S. J., Perrot, A., Alegre, A. M., Simpson, D., Wang, M. C., Spencer, A. G., Delimpasi, S., Hulin, C., Sunami, K., Facon, T. T. F., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17499 · Cited by 50
Self-citationMultiple Myeloma: From Front-Line to Relapsed Therapies
Moreau, P., & Touzeau, C. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e504 · Cited by 48
Self-citationPD-1/PD-L1 inhibitors in multiple myeloma: The present and the future
Jelinek, T., & Hajek, R. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1254856 · Cited by 45
Self-citationBondar, D., & Karpichev, Y. (2024) · Biomolecules · doi:10.3390/biom14101269 · Cited by 49
“Continued innovation and research are essential to fully unlocking their potential, not just in cancer therapy but possibly in treating other diseases as well.”
BackgroundNF-κB dysregulation in multiple myeloma
Matthews, G. M., Simoes, R. D. M., Dhimolea, E., Sheffer, M., Gandolfi, S., Dashevsky, O., Sorrell, J., & Mitsiades, C. S. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.08.005 · Cited by 53
MR imaging of atypical fibroids
Bolan, C. W., & Caserta, M. P. (2016) · Abdominal Radiology · doi:10.1007/s00261-016-0935-0 · Cited by 48
Leleu, X. P., Masszi, T., Bahlis, N. J., Viterbo, L., Baker, B., Gimsing, P., Maisnar, V., Samoilova, O. S., Rosiñol, L., Langer, C., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25134 · Cited by 50
Self-citationChakraborty, R., Riaz, I. B., Malik, S. U., Marneni, N., Garcia, A. M., Anwer, F., Khorana, A. A., Rajkumar, S. V., Kumar, S. K., Murad, M. H., et al. (2020) · Cancer · doi:10.1002/cncr.32682 · Cited by 51
Self-citationBruno, A. S., Willson, J., Opalińska, J., Nelson, J. J., Lunacsek, O. E., Stafkey-Mailey, D., & Willey, J. P. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1800451 · Cited by 50
Kidney injury and disease in patients with haematological malignancies
Bridoux, F., Cockwell, P., Glezerman, I. G., Gutgarts, V., Hogan, J. J., Jhaveri, K. D., Joly, F., Nasr, S. H., Sawinski, D. L., & Leung, N. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00405-7 · Cited by 48
Immunotherapy in Multiple Myeloma
Soekojo, C. Y., Ooi, M. G. M., Mel, S. D., & Chng, W. J. (2020) · Cells · doi:10.3390/cells9030601 · Cited by 49
Comerford, C., Glavey, S. V., Quinn, J., & O’Sullivan, J. M. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15773 · Cited by 49
Raje, N. S., Moreau, P., Terpos, E., Benboubker, L., Grząśko, N., Holstein, S. A., Oriol, A., Huang, S., Beksaç, M., Kuliczkowski, K., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14483 · Cited by 48
Self-citationMultiple myeloma cells’ capacity to decompose H2O2 determines lenalidomide sensitivity
Sebastian, S., Zhu, Y. X., Braggio, E., Shi, C.-X., Panchabhai, S. C., Wier, S. A. V., Ahmann, G. J., Chesi, M., Bergsagel, P. L., Stewart, A. K., et al. (2016) · Blood · doi:10.1182/blood-2016-09-738872 · Cited by 47
Self-citationZhou, X., Flüchter, P., Nickel, K., Meckel, K., Messerschmidt, J., Böckle, D., Knorz, S., Steinhardt, M., Krummenast, F., Danhof, S., et al. (2020) · Cancers · doi:10.3390/cancers12041035 · Cited by 48
Kuwahara‐Ota, S., Shimura, Y., Steinebach, C., Isa, R., Yamaguchi, J., Nishiyama, D., Fujibayashi, Y., Takimoto‐Shimomura, T., Mizuno, Y., Matsumura‐Kimoto, Y., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16881 · Cited by 45
Siegel, D. S., Schiller, G. J., Song, K. W., Agajanian, R., Stockerl‐Goldstein, K., Kaya, H., Sebag, M., Samaras, C., Malek, E., Talamo, G., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16213 · Cited by 46
Self-citationTreatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Dimopoulos, M.-A., Richardson, P., & Lonial, S. (2022) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2022.01.011 · Cited by 46
Self-citationRecent progress in relapsed multiple myeloma therapy: implications for treatment decisions
Moreau, P., & de Wit, E. (2017) · British Journal of Haematology · doi:10.1111/bjh.14780 · Cited by 46
Self-citationDimopoulos, M., Wang, M., Maisnar, V., Minarik, J., Bensinger, W., Mateos, M.-V., Obreja, M., Blaedel, J., & Moreau, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0583-7 · Cited by 44
“We found that in patients who had high-risk cytogenetics or one or more prior lines of therapy, PFS HRs favored KRd versus Rd in the first 18 months and were lower than the HR for the overall ASPIRE study [25].”
BackgroundMethodResultSelf-citationStrategies to improve patient-reported outcome completion rates in longitudinal studies
Nielsen, L. K., King, M. T., Möller, S., Jarden, M., Andersen, C. L., Frederiksen, H., Gregersen, H., Klostergaard, A., Steffensen, M., Pedersen, P. T., et al. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02304-8 · Cited by 47
How I treat high-risk multiple myeloma
Zamagni, E., Barbato, S., & Cavo, M. (2021) · Blood · doi:10.1182/blood.2020008733 · Cited by 48
Gasparetto, C., Schiller, G. J., Tuchman, S. A., Callander, N. S., Baljević, M., Lentzsch, S., Rossi, A., Kotb, R. R., White, D. J., Bahlis, N. J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01608-2 · Cited by 46
“Moreover, some of the most common AEs associated with carfilzomib, but not selinexor, were lower or similar in the current trial compared to other pivotal clinical trials testing carfilzomib in triplet combinations [35, 36].”
ResultSelf-citationPathogenesis and treatment of multiple myeloma
Yang, P., Qu, Y., Wang, M., Chu, B., Chen, W., Zheng, Y., Niu, T., & Qian, Z. (2022) · MedComm · doi:10.1002/mco2.146 · Cited by 54
Self-citationCosta, L. J., Lin, Y., Cornell, R. F., Martin, T. G., Chhabra, S., Usmani, S. Z., Jagannath, S., Callander, N. S., Berdeja, J. G., Kang, Y., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.10.013 · Cited by 47
Sonneveld, P., de Wit, E., & Moreau, P. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.007 · Cited by 46
Self-citationEmerging drugs and combinations to treat multiple myeloma
Larocca, A., Mina, R., Gay, F., Bringhen, S., & Boccadoro, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19269 · Cited by 46
“7% of patients discontinued treatment owing to adverse events [55].”
BackgroundCD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
Frerichs, K. A., Nagy, N. A., Lindenbergh, P. L., Bosman, P., Soto, J. A. M., Broekmans, M. E. C., Groen, R. W. J., Themeli, M., Nieuwenhuis, L., Stege, C. A. M., et al. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1443809 · Cited by 48
“Other approved triplets which do not incorporate antibodies include carfilzomib plus Rd [91] and ixazomib [92] (an oral PI) plus Rd.”
BackgroundChemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis
Hassan, S. A., Palaskas, N. L., Kim, P. Y., Iliescu, C., Lopez‐Mattei, J., Mouhayar, E., Mougdil, R., Thompson, K., Banchs, J. A., & Yusuf, S. W. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0702-5 · Cited by 45
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity
Rocca, C., Francesco, E. M. D., Pasqua, T., Granieri, M. C., Bartolo, A. D., Cantafio, M. E. G., Muoio, M. G., Gentile, M., Neri, A., Angelone, T., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030520 · Cited by 47
Hari, P., Romanus, D., Luptakova, K., Blazer, M. A., Yong, C., Raju, A., Farrelly, E., Labotka, R., & Morrison, V. A. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.09.007 · Cited by 46
Mushtaq, A., Kapoor, V., Latif, A., Iftikhar, A., Zahid, U., McBride, A., Abraham, I. L., Riaz, I. B., & Anwer, F. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.02.008 · Cited by 46
Landgren, O., & Owen, R. G. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21273 · Cited by 44
Cardiovascular Complications of Novel Multiple Myeloma Treatments
Li, W., Cornell, R. F., Lenihan, D. J., Slosky, D., Jagasia, M., Piazza, G., & Moslehi, J. J. (2016) · Circulation · doi:10.1161/circulationaha.115.018351 · Cited by 44
Bechakra, M., Nieuwenhoff, M. D., van Rosmalen, J., Groeneveld, G. J., Boer, M. S., Sonneveld, P., van Doorn, P. A., Zeeuw, C. I. D., & Jongen, J. L. M. (2018) · Molecular Pain · doi:10.1177/1744806918797042 · Cited by 48
Dimopoulos, M. A., Siegel, D. S. D., White, D. J., Boccia, R. V., Iskander, K. S., Yang, Z., Kimball, A. S., Mezzi, K., Ludwig, H., & Niesvizky, R. (2018) · Blood · doi:10.1182/blood-2018-06-860015 · Cited by 45
Self-citationChari, A., Richardson, P. G. G., Romanus, D., Dimopoulos, M. A., Sonneveld, P., Terpos, E., Hájek, R., Raju, A., Palumbo, A. P., Cain, L. E., et al. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1729734 · Cited by 45
Self-citationBringhen, S., D’Agostino, M., París, L., Ballanti, S., Pescosta, N., Spada, S., Pezzatti, S., Grasso, M., Rota‐Scalabrini, D., Rosa, L. D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.226407 · Cited by 44
“* At least one among deletion 17p [del(17p)], translocation (4;14) [t(4;14)] or translo-”
BackgroundSelf-citationTerpos, E., Ramasamy, K., Maouche, N., Minařík, J., Ntanasis‐Stathopoulos, I., Katodritou, E., Jenner, M. W., Plonková, H., Gavriatopoulou, M., Vallance, G. D., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03981-z · Cited by 43
Self-citationGenome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 48
Multiple myeloma—translation of trial results into reality
Moreau, P., & Rajkumar, S. V. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30954-0 · Cited by 47
Self-citation
Metadata
- Authors
- Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W. I., Mateos, M.-V., Ben-Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M. E., Yang, X., Xing, B., Moreau, P., & Palumbo, A.
- Affiliations
- Mayo Clinic in Arizona (US)
- Mayo Clinic (US)
- Alexandra Hospital (GR)
- Semmelweis University (HU)
- Josep Carreras Leukaemia Research Institute (ES)
- University of Ostrava (CZ)
- Hospital Clínic de Barcelona (ES)
- Hackensack University Medical Center (US)
- Queen Giovanna Hospital (BG)
- University Multipurpose Hospital for Active Treatment "Sveti Georgi" (BG)
- Somogy Megyei Kaposi Mór Oktató Kórház (HU)
- The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic (RU)
- University of Chicago (US)
- Wilhelminen Hospital (AT)
- The University of Texas MD Anderson Cancer Center (US)
- Charles University (CZ)
- Fred Hutch Cancer Center (US)
- Princess Margaret Cancer Centre (CA)
- Université de Nantes (FR)
- University of Turin (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-08
- Volume
- 372
- Issue
- 2
- Pages
- 142-152
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1985864219
- Semantic Scholar
- 6c229c6500f2d44efe03b42aea66351261666d13
- Cited by
- 1,332
- References
- 33
- Citations by year
- 2026: 36 · 2025: 62 · 2024: 63 · 2023: 79 · 2022: 112 · 2021: 137 · 2020: 149 · 2019: 131 · 2018: 166 · 2017: 168 · 2016: 148 · 2015: 77
- FWCI
- 93.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- carfilzomib, lenalidomide, dexamethasone, relapsed multiple myeloma, proteasome inhibitors, progression-free survival, overall survival, adverse events, health-related quality of life, combination therapy, treatment response, interim analysis, treatment discontinuation, stringent complete response, partial response, complete response, overall response rate
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Oligopeptides, Recurrence, Thalidomide, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.